Hyaluronan inhibits matrix metalloproteinase-13 in human arthritic chondrocytes via CD44 and P38

Journal of Orthopaedic Research

Volumn 29, Issue 2, 2011, Pages 258-264

  Julovi, Sohel M ^a,b   Ito, Hiromu ^a   Nishitani, Kohei ^a   Jackson, Christopher J ^b   Nakamura, Takashi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

arthritic chondrocytes; CD44; hyaluronan; interleukin 1 ; matrix metalloproteinase 13; p38 kinase

Indexed keywords

CD44V ANTIGEN; COLLAGENASE 3; HYALURONIC ACID; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; OSTEOARTHRITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANTIGENS, CD44; ARTHRITIS; CELLS, CULTURED; CHONDROCYTES; HUMANS; HYALURONIC ACID; INTERLEUKIN-1BETA; MATRIX METALLOPROTEINASE 13; P38 MITOGEN-ACTIVATED PROTEIN KINASES; VISCOSUPPLEMENTS;

EID: 78650934811     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21216     Document Type: Article

References (37)

1. Moldovan F, Pelletier JP, Hambor J, et al. 1997. Collagenase-3 (matrix metalloprotease 13) is preferentially localized in the deep layer of human arthritic cartilage in situ: in vitro mimicking effect by transforming growth factor beta. Arthritis Rheum 40: 1653-1661.
2. Arend WP, Dayer J-M,. 1995. Inhibition of the production and affects of interleukin-1 and tumor necrosis factor-α in rheumatoid arthritis. Arthritis Rheum 38: 151-160.
3. Mengshol JA, Vincenti MP, Coon CI, et al. 2000. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum 43 (4): 801-811.
4. Pendas AM, Balbin M, Llano E, et al. 1997. Structural analysis and promoter characterization of human collagenase-3 gene (MMP-13). Genomics 40 (2): 222-233.
5. Brown TJ, Laurent UB, Fraser JR,. 1991. Turnover of hyaluronan in synovial joints: elimination of labeled hyaluronan from the knee joint of the rabbit. Exp Physiol 76: 125-134.
6. Henderson EB, Smith EC, Pegley F, et al. 1994. Intra-articular injections of 750kDa hyaluronan in the treatment of osteoarthritis: a randomised single centre double-blind placebo-controlled trial of 91 patients demonstrating lack of efficacy. Ann Rheum Dis 53: 529-534.
7. Lo GH, LaValley M, McAlindon T, et al. 2003. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. J Am Med Assoc 290: 3115-3121.
8. Wobig M, Dickhut A, Maier R, et al. 1998. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther 20: 410-423.
9. Huskisson EC, Donnelly S,. 1999. Hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatology (Oxford) 38: 602-607.
10. Goldberg VM, Buckwalter JA,. 2005. Hyaluronans in the treatment of osteoarthritis of the knee: evidence for disease-modifying activity. Osteoarthritis Cartilage 13 (3): 216-224.
11. Wang CT, Lin J, Chang CJ, et al. 2004. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials. J Bone Joint Surg Am 86-A (3): 538-545.
12. Goto M, Hanyu T, Yoshio T, et al. 2001. Intra-articular injection of hyaluronate (SI-6601D) improves joint pain and synovial fluid prostaglandin E2 levels in rheumatoid arthritis: a multicenter clinical trial. Clin Exp Rheumatol 19 (4): 377-383.
13. Fraser JR, Laurent TC, Laurent UB,. 1997. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med 242 (1): 27-33.
14. Listrat V, Ayral X, Patarnello F, et al. 1997. Arthroscopic evaluation of potential structure modifying activity of hyaluronan (Hyalgan) in osteoarthritis of the knee. Osteoarthritis Cartilage 5: 153-160.
15. Ohno S, Im HJ, Knudson CB, et al. 2005. Hyaluronan oligosaccharide- induced activation of transcription factors in bovine articular chondrocytes. Arthritis Rheum 52 (3): 800-809.
16. Julovi SM, Yasuda T, Shimizu M, et al. 2004. Inhibition of interleukin-1β-stimulated production of matrix metalloproteinases by hyaluronan via CD44 in human articular cartilage. Arthritis Rheum 50 (2): 516-525.
17. Altman R, Asch E, Bloch D, et al. 1986. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 29: 1039-1049.
18. Arnett FC, Edworthy SM, Bloch DA, et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (3): 315-324.
19. Kleemann RU, Krocker D, Cedraro A, et al. 2005. Altered cartilage mechanics and histology in knee osteoarthritis: relation to clinical assessment (ICRS Grade). Osteoarthritis Cartilage 13: 958-963.
20. Yasuda T, Julovi SM, Hiramitsu T, et al. 2004. Requirement of mitogen-activated protein kinase for collagenase production by fibronectin fragment in human articular chondrocytes in culture. Mod Rheumatol 14 (1): 54-60.
21. Labarca C, Paigen K,. 1980. A simple, rapid, and sensitive DNA assay procedure. Anal Biochem 102 (2): 344-352.
22. Julovi SM, Ito H, Hiramitsu T, et al. 2008. Hyaluronan inhibits IL-1β-stimulated collagenase production via down-regulation of phosphorylated p38 in SW-1353 human chondrosarcoma cells. Mod Rheumatol 18: 263-270.
23. Balazs EA, Watson D, Duff IF, et al. 1967. Hyaluronic acid in synovial fluid. Molecular parameters of hyaluronic acid in normal and arthritic human fluids. Arthritis Rheum 10: 357-376.
24. Dahl LB, Dahl IM, Laurent AE, et al. 1985. Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann Rheum Dis 44 (12): 817-822.
25. Jiang D, Liang J, Noble PW,. 2007. Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol 23: 435-461.
26. Anandacoomarasamy A, Bagga H, Ding C, et al. 2008. Predictors of clinical response to intraarticular hylan injectionsâa prospective study using synovial fluid measures, clinical outcomes, and magnetic resonance imaging. J Rheumatol 35 (4): 685-690.
27. Wernicke D, Seyfert C, Gromnica-Ihle E, et al. 2006. The expression of collagenase 3 (MMP-13) mRNA in the synovial tissue is associated with histopathologic type II synovitis in rheumatoid arthritis. Autoimmunity 39 (4): 307-313.
28. Schett G, Tohidast-Akrad M, Smolen JS, et al. 2000. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 43 (11): 2501-2512.
29. Yatabe T, Mochizuki S, Takizawa M, et al. 2009. Hyaluronan inhibits expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic chondrocytes. Ann Rheum Dis 68: 1051-1058.
30. Liacini A, Sylvester J, Li WQ, et al. 2002. Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol 21 (3): 251-262.
31. Pei Y, Harvey A, Yu XP, et al. 2006. Differential regulation of cytokine-induced MMP-1 and MMP-13 expression by p38 kinase inhibitors in human chondrosarcoma cells: potential role of Runx2 in mediating p38 effects. Osteoarthritis Cartilage 14 (8): 749-758.
32. Badger AM, Bradbeer JN, Votta B, et al. 1996. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 279 (3): 1453-1461.
33. Mengshol JA, Vincenti MP, Brinckerhoff CE,. 2001. IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells: requirement for Runx-2 and activation by p38 MAPK and JNK pathways. Nucleic Acids Res 29 (21): 4361-4372.
34. Han Z, Boyle DL, Aupperle KR, et al. 1999. Jun N-terminal kinase in rheumatoid arthritis. J Pharmacol Exp Ther 291: 124-130.
35. Naor D, Nedvetzki S,. 2003. CD44 in rheumatoid arthritis. Arthritis Res Ther 5: 105-115.
36. Bannuru RR, Natov NS, Obadan IE, et al. 2009. Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Arthritis Rheum 61 (12): 1704-1711.
37. Altman RD, Rosen JE, Bloch DA, et al. 2009. A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial). Semin Arthritis Rheum 39 (1): 1-9.